Small-Cap Stock Faceoff: Which Medical Device Company Is the Smarter Investment?

Last week, two medical device companies reported Q1 2026 earnings. Both blew estimates out of the water.

A note from our sponsors...

"This stock has a 93% history of soaring, every spring"

One of the most popular stocks in America has a 100% history of rising on one particular date - every single spring.

In fact, it's gone up beginning this ONE specific day - year after year - at a rate fast enough to double your money in 12 months.

Click here to see the name of the stock, free of charge.

Analysts expected Tactile Systems (NASDAQ: TCMD) to bring in a loss of 12 cents per share. The loss came in at 8 cents. At the same time, Wall Street expected Bioventus (NASDAQ: BVS) to post a gain of 7 cents per share — only for BVS to report 15 cents.

Now, if you think the fact that TCMD posted a loss while BVS posted a gain makes this an open-and-shut case, hold your horses. TCMD outperformed estimates — revenue grew by 23%, but higher R&D, admin, and marketing costs drew down earnings. In fact, TCMD has surged by about 14% since that earnings call.

So, it’s not an open-and-shut case — but I didn’t say there’s no case. We’re still left with the question of which of these companies is the better play right now. They’re in the same industry, and both of the tickers are small-caps, so comparing them is sensible.

Here’s what we’re gonna do. We’re going to look at the fundamental picture on both, and I’m going to let you decide for yourself. I am, however, going to give you my take.

Stay with me to see which is the clear winner…

At WallStreetZen, we have our own in-house quant rating model. It looks at about 4,600 stocks on a daily basis, taking into account 115 factors and metrics split across 7 categories. A stock’s overall fundamental strength is measured by its Zen Rating. Only the stocks that rank in the top 5% are given a Zen Rating of A — and stocks with that distinction have provided an average annual return of 32.52% since the early 2000s.

Those 7 categories I mentioned are called Component Grade ratings — and they can clue us in on a stock’s specific strengths or weaknesses.

Okay — so now that you’ve got the terminology down pat, we can begin.

First, the big-picture overview. Both of these stocks have a Zen Rating of A. Right now, TCMD ranks in the top 3%, while BVS ranks in the top 1%.

To find the real differences, we’ve gotta dig into those Component Grade ratings. I’ll put them down below — TCMD on the left, BVS on the right.

This is where things get interesting. There’s not a single area where Tactile Systems ranks better than Bioventus. On the flip side, there’s plenty of areas where BVS ranks better than TCMD.

We’re not gonna go through all the ratings, in the interest of time — but we are gonna go through the most important ones. Value — Tactile clocks in at the top 11%, while Bioventus is in the top 4%. TCMD is trading at a PEG of 0.94x and a price-to-earnings (P/E) ratio of 28.82x. Meanwhile, BVS is trading at a PEG of 0.73x and a P/E of 24.42x. The disparity in valuation relative to growth is the most jarring. Simply put, BVS is undervalued — TCMD is not.

When it comes to Growth , TCMD ranks in the 66th percentile — equivalent to or better than 66% of stocks. BVS, on the other hand, ranks in the 98th percentile — so, equivalent to or better than 98% of stocks. The expected earnings growth on both names is similar — but Bioventus has demonstrated stronger execution. BVS has beaten estimates for 12 quarters in a row — that’s 3 straight years. TCMD is also on a streak — but that streak is 4 quarters long.

Financials — Tactile is in the top 14% here. Bioventus is in the top 7%. Both boast healthy balance sheets, but there’s a gap that works in Bioventus’ favor. Safety — top 14% for TCMD, top 8% for BVS.

And last but not least, we have Sentiment; the smart money rating. Top 26% for Tactile Systems, top 1% for Bioventus.

If I’m being perfectly honest, we could have kept this down to just Value and Growth — but I wanted to present a slightly wider picture to you.

TCMD is by no means a bad stock. On the whole, it’s actually quite good — but right now, all the fundamentals point to Bioventus as the better choice. You should take a closer look at both and do your own research — but for me, the stronger execution and better valuation of Bioventus make it the clear winner here.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.